Neuberg and NM Medical’s merger strengthens Maharashtra’s preventive healthcare network, combining advanced diagnostics, imaging and wellness services with a Rs 500 crore revenue target.
Sterile drug licensing in India could shift to CDSCO as the Centre examines central oversight following 240 NSQ injection samples in 2025-26.
Aurobindo Pharma CNS portfolio expands with perampanel, adding to recent epilepsy approvals as its USFDA ANDA count reaches 599.
UP hospital bills face scrutiny as medicine price gaps widen inside treatment packages, raising questions over mark-ups, discounts and patient costs.
The government extends import price curbs on two pharma raw materials, offering domestic producers temporary relief from low-priced Chinese supplies.
India powers primary care through 1.86 lakh Ayushman Arogya Mandirs, delivering 420 million screenings and expanding preventive healthcare nationwide.
Pharma pricing faces tighter scrutiny this month as courts, state regulators and global agreements target drug, device and hospital supply-chain markups.
India is positioned to gain as the US zeroes tariffs on key specialty drugs, creating new opportunities for Indian pharma manufacturers.
Apixaban oral suspension is Lupin's latest formulation development, receiving tentative US FDA approval for its 1.25 mg/mL product as an alternative to tablets.
AIIMS Delhi secures approval for a major critical care capacity boost, adding a dedicated infectious diseases block and multi-level parking at JPN Apex Trauma Center.
.jpg)
, CDSCO.jpg)
